Lung cancer is usually divided in four major types: small cell carcinoma (representing 25%), epidermoid carcinoma (30%), adenocarcinoma (25%) and large-cell carcinoma (15%), with uncommon or mixed types making up the remaining 5% (Sobin, 1982) . The distinction between small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) is clinically important because SCLC is treated mostly with chemotherapy while the treatment of choice in NSCLC is surgery. NSCLC, in turn, comprises a heterogeneous group of tumours, the classification of which might possibly be improved by determining the activation of protooncogenes in the tumours. It is hoped that elucidation of the genetic mechanisms in lung cancer will eventually result in the design of improved treatment strategies.
The primary candidates in the search for the pathogenic mechanisms in cancer are the known cellular protooncogenes, which have been shown to be important in the transformation of cells in several model systems (for review see Varmus, 1984) . Activation of these oncogenes can result from several mechanisms, including gene amplification, allelic deletion, gene rearrangement or certain (point-) mutation(s) in the protooncogene sequences (for reviews see Nishimura & Sekiya, 1987; Alitalo & Schwab, 1986) . In some cases protooncogene activation correlates well with tumour type or with biological behaviour of the tumour (Yokota et al., 1986b; Seeger et al., 1986; Slamon et al., 1987) . Of the known protooncogenes, only a few have been found to be consistently altered in human lung carcinoma (for review see Rodenhuis, 1988) . Amplification of the cellular protooncogenes of the myc family has been observed in primary SCLC tumours in several studies (Nau et al., 1985; Wong et al., 1986; Brooks et al., 1987) , and has in some cases been correlated with clinical behaviour Funa et al., 1987) . In NSCLC, several protooncogene aberrations have been described, including amplification of c-myc (Yokota et al., 1986b; Cline & Battifora, 1987) , N-myc (Saksela et al., 1986) , ras (Pulciani et al., 1985; Vousden et al., 1986) , erbB (Yokota et al., 1986a; Cline & Battifora, 1987; Berger et al., 1987) , and neu (Cline & Battifora, 1987) genes. Other genetic abnormalities, such as loss of H-ras and myb alleles (Cline & Battifora, 1987) or chromosomal deletion of an unknown gene on the short arm of chromosome 3 (Naylor et al., 1987; Kok et al., 1987) have also been reported. We have previously shown that the K-ras protooncogene is activated by point-mutation in about a third of all adenocarcinomas of the lung (Rodenhuis et al., 1987 (Sobin, 1982) . The four remaining tumours were a carcinoid and three lung metastases, three from colorectal and one from a breast primary (Table I) . Classification of the tumour specimens was done independently by two diagnostic histopathologists (S.S.W. and W.J. Mooi). Clinical parameters such as tumour size, tumour spread, smoking habits, interval to recurrence, etc., were obtained by reviewing the hospital charts. The cell lines A549 and NCI-H23 have been described previously (Lieber et al., 1976; Carney et al., 1985) . The GLC-Al and GLC-A2 cell lines are human lung adenocarcinoma cell lines and were a gift from Dr L.F.H.M. de Leij from the University of Groningen, The Netherlands.
DNA was isolated using standard techniques and used for dot-blotting and for Southern blotting as described previously (Rodenhuis et al., 1987) . For Southern blotting the samples were digested with the indicated restriction enzymes (obtained from Boehringer Mannheim, Mannheim, Federal Republic of Germany), separated on 0.8% agarose gels and blotted onto Hybond membranes (Amersham International, Amersham, UK) using procedures as indicated by the manufacturer. Protooncogene probes were nick-translated and hybridised to the filters using standard techniques (Janssen et al., 1985) . The following molecular probes were used: H-ras 'pEJ' (Goldfarb et al., 1982) , K-ras 'pLC3' (Shimizu et al., 1983) , N-ras 'clone B' (Hall et al., 1983) , c-myc 'pMC-413RC' (Dalla-Favera et al., 1982b) , N-myc 'pNB-l' (Schwab et al., 1983) , L-myc 'pLmyclO' (Nau et al., 1985) , erbB 'fragment III' (Ullrich et al., 1984) , mos 'pHBl' (Watson et al., 1982) , myb 'pHM2.8' (Leprince et al., 1983) , and neu 0.4kb BamHI cDNA fragment (Bargmann et al., 1986) . After hybridisation the blots were washed at a final stringency of 0.1 x SSC (SSC is 0.15 mol sodium chloride and 0.015 mol trisodium citrate per litre) at 65°C. Control hybridisations were done with actin encoding sequences from the pACT-1 plasmid (Dodemont et al., 1982) , with a final wash done in 2xSSC, and 0.5% SDS at 55°C. Autoradiography was performed with Kodak XAR-5 of XS-1 films at -70°C using an intensifying screen. Amplifications were quantified using dot-blot dilution series of the DNAs of tumours containing protooncogene amplifications. A total of 52 DNAs from human non-small cell lung carcinomas were studied. The histology data of the tumours from which the DNA was isolated are presented in Table I Figure 1 an example of such a hybridisation is shown. After separate hybridisations of these Southern blots, no abnormal copy numbers of the N-ras, ral or myb gencs could be detected. The H-ras gene hybridisation is described below. Hybridisation with the K-ras probe revealed as 15-20-fold amplification in a solitary lung metastasis of colorectal origin which we described previously (Rodenhuis et al., 1987) , but no K-ras gene amplifications in the other tumour specimens.
All tumour DNAs were analysed on Southern blots after digestion with HindIlI. These blots were hybridised with the probes for the three myc, the erbB, mos and H-ras genes. As shown in Figure 2 , the H-ras gene was found amplified 3- Figure 2 an amplification of the c-myc gene in an adenocarcinoma is presented. In Figure 3 the Southern blot hybridisations are shown of six representative, Hindlll digested tumour DNA samples hybridised with probes for c-myc, L-myc and N-myc as well as for erbB and mos. In lane 4 the probe for c-myc detects a 5-7-fold amplification of this gene. This stronger signal is not seen with either the N-or L-myc protooncogene probes. Amplification of a c-myc gene could be detected in two of 48 tumours, both of which were adenocarcinomas (Table II) . The N-and L-myc genes were not amplified in any of the DNAs we investigated, and neither was the erbB gene.
Discussion
Activation of protooncogenes by amplification is a well studied mechanism that has been reported for several primary human tumours. These include c-myc in SCLC and NSCLC and in other cancers, N-myc in neuroblastoma, retinoblastoma and chronic myeloid leukaemia, c-myb in acute myeloid leukaemia, H-ras and K-ras in bladder carcinoma, and neu in adenocarcinomas of the stomach and breast. Amplifications have also been found in many cell lines derived from human tumours (for reviews see Nishimura & Sekiya, 1987; Alitalo & Schwab, 1986 In 48 primary NSCLC and in four NSCLC derived cell lines no amplifications of the cellular protooncogenes myb or mos were detected. Since the c-mos gene is localised on chromosome 8 in the same region as c-myc, the detected increased copy numbers of c-myc are likely to result from gene amplification rather than from chromosome duplication.
Although several reports indicate that the c-erbB protooncogene, encoding the epidermal growth factor receptor (EGFR), has a role in the carcinogenesis of human lung cancer, we did not find any abnormal copy numbers of this gene. Recently published data on this subject indicate that enhanced levels of the EGFR frequently occur in epidermoid lung carcinomas (Berger et al., 1987) and less commonly in other NSCLC types (Veale et al., 1987) . High expression of erbB does not necessarily require amplification of the gene, as has been shown in a study including 25 NSCLC (Lee et al., 1987) . Furthermore, high expression of the EGFR has been observed in several different tumour types and cell lines without amplification of the gene (Alitalo & Schwab, 1986) . Although the erbB gene has been found amplified in some NSCLCs (Cline & Battifora, 1987) , overexpression of the EGF receptor without amplification appears to occur much more frequently. These data combined with our findings indicate that activation by amplification of the erbB gene may represent only a minority of the activational mechanisms of increased EGFR expression.
Similar to the apparent involvement of the erbB gene in the carcinogenesis of epidermoid tumours, the neu protooncogene may have a role in the pathogenesis of adenocarcinomas. This gene has been reported to be amplified in five of 63 glandular tumours, but not in the three adenocarcinomas of the lung which were also investigated (Yokota et al., 1986a) . In about 20% of breast carcinomas the neu gene is found amplified (Van De Vijver et al., 1987) , a phenomenon that appears to have clinical implications (Slamon et al., 1987) . This report shows that in 21 lung adenocarcinomas not a single amplified neu gene was present. We thus conclude that this gene is not frequently amplified in NSCLC. The only case of a neu amplification we did detect was in a solitary lung metastasis of a breast carcinoma. A similar case of neu amplification in a lung metastasis from a breast primary has been described for a case in which the primary tumour had normal copy numbers of the gene (Yokota et al., 1986a) . Thus, amplification of the neu gene might in some cases aid in distinguishing different types of adenocarcinoma.
Members of the ras family of protooncogenes are expressed in many normal and tumour cells (for review see Bos, 1988) . These genes have been described as being altered in human lung tumours by amplification (Pulciani et al., 1985; Vousden et al., 1986) as well as by point mutation (Rodenhuis et al., 1987) , both types of activation also being frequently observed in cell lines (Nishimura & Sekiya, 1987) . In our series of NSCLC specimens we have described the frequent (about 30%) mutational activation of the K-ras gene in lung adenocarcinomas, but not in other types of NSCLC . The K-ras and N-ras protooncogenes were not amplified in any of the primary lung carcinomas. This result is in agreement with other studies (Heighway & Hasleton, 1986; Cline & Battifora, 1987) . The only ras amplification we found in this study was of the H-ras gene in a single adenocarcinoma, which was Kras mutation negative. This is the first time an H-ras protooncogene amplification is detected in a fresh tumour specimen of a NSCLC. In general, however, amplifications of the ras genes are rare in NSCLC.
Ras gene abnormalities in lung metastases of colorectal origin seem to occur more frequently: of four studied samples one had a K-ras amplification, while two others harboured ras gene mutations, one in N-ras cordon 61 and one in K-ras codon 12 . These mutations are known to occur with some frequency in colon cancers (Bos et al., 1987) . Thus, three of four colorectal metastases to the lung (including one we did not test for ras amplification) contain an activated ras protooncogene. It is (Egan et al., 1987) , and a system of mouse Tlymphoma cells (Collard et al., 1987) . The myc family of protooncogenes has frequently been found to be altered in lung cancer, although most of the data focus on SCLC and SCLC-derived cell lines. The latter tend to have amplified myc genes Kiefer et al., 1987) , which is reflected by overexpression at the mRNA level (Ibson et al., 1987) . Amplifications of the cellular myc genes in primary SCLC have also been described, but these occur with much lower frequency than in SCLC cell lines (Saksela et al., 1986; Wong et al., 1986) . For NSCLC only a few studies report myc gene amplifications in primary tumours. The c-myc gene was observed to be amplified in one of two bronchioloalveolar carcinomas (Yokota et al., 1986b) , and in three of 26 NSCLC, all adenocarcinomas (Cline & Battifora, 1987) . Our findings confirm that the c-myc protooncogene is amplified in a minority of NSCLCs, in our study two of 48 samples, one large-cell carcinoma and one adenocarcinoma. It thus appears that the c-myc amplifications, though infrequent in NSCLCs, mainly occur in adenocarcinomas. In SCLC, c-myc amplification has been reported to correlate with a poor prognosis . Whether or not this is also the case in NSCLC cannot be determined at present.
Two other members of the myc gene family, N-myc and Lmyc (Schwab et al., 1983; Nau et al., 1985) , commonly amplified in SCLC cell lines, have occasionally been described to be amplified in uncultured lung tumours (Minna et al., 1986; Saksela et al., 1986) . In our series no N-or Lmyc amplifications could be detected. An important role for amplification of these genes in NSCLC is thus unlikely. Future investigations will have to elucidate the occurrence of other myc gene activations such as overexpression or translocation in NSCLC.
Since we previously screened in NSCLC DNAs for mutational activation of the cellular ras genes (Rodenhuis et al., 1987 , the simultaneous presence of an amplified protooncogene with a mutated ras gene could be examined. At least for one lung carcinoma xenograft maintained in nude mice it has been described that an amplified and mutationally activated K-ras gene can occur simultaneously with an amplified c-myc gene (Taya et al., 1984) . Despite the relatively high frequency of K-ras codon 12 mutations in our series, we did not detect alterations of more than a single protooncogene. Thus it seems probable that one or more yet unidentified protooncogenes can complement for K-ras mutations and/or protooncogene amplifications in the pathogenesis of human lung cancer.
